Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
复制标题
DOI：
10.5754/hge11263
复制
发表时间：
2011-11-01
影响因子：
--
通讯作者：
Nakajima, Atsushi
中科院分区：
文献类型：
--
作者：
Iwasaki, Tomoyuki;Yoneda, Masato;Nakajima, Atsushi
背景/目的：非酒精性脂肪性肝病（NAFLD）是慢性肝损伤最常见的原因，被认为是代谢综合征的肝脏表现。然而，尚未建立有效的NAFLD药物治疗。在本研究中，我们评估了西格列汀治疗NAFLD合并2型糖尿病（DM）患者4个月的疗效。方法：我们评估了30例NAFLD合并2型糖尿病患者。超声诊断NAFLD。患者接受西格列汀（50 mg/人/天）治疗4个月。结果如下：西格列汀治疗4个月后，观察到血糖和血清HbA 1c、AST、ALT和γ-GTP水平显著降低。结论：在本研究中，西格列汀治疗不仅改善了糖尿病参数，而且改善了肝脏检查参数。我们的研究证明了西格列汀在NAFLD合并2型DM患者中的疗效，这表明未来有必要进行大规模的临床试验。
Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury, and is considered as the hepatic manifestation of metabolic syndrome. However, no effective drug therapy for NAFLD has been established yet. In the present study, we evaluated the efficacy of 4 months of treatment with sitagliptin in NAFLD patients with type 2 diabetes mellitus (DM). Methodology: We evaluated 30 NAFLD patients with type 2 DM. NAFLD was diagnosed by ultrasonography. The patients were administered sitagliptin (50mg/body/day) for 4 months. Results: Significant decreases of the plasma glucose and serum HbA1c, AST, ALT and gamma-GTP levels were observed after 4 months of treatment with sitagliptin. Conclusions: In this study, not only the parameters of diabetes, but also those of liver tests were improved by the treatment with sitagliptin. Our study demonstrated the efficacy of sitagliptin in NAFLD patients with type 2 DM, suggesting that a large-scale clinical trial is warranted in the future.